XHRPXF7
Replacement Skin to New Technology Group 7 with Bioengineered Allogeneic Construct, External Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | H Skin, Subcutaneous Tissue, Fascia and Breast |
| Operation | R Replacement |
| Body Part | P Skin |
| Approach | X External |
| Device | F Bioengineered Allogeneic Construct |
| Qualifier | 7 New Technology Group 7 |
Operation Definition
Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part
Procedure Overview
This family covers using an advanced synthetic or biological material to physically take the place of skin, subcutaneous tissue, fascia, or breast tissue that has been removed or damaged, most commonly seen in breast reconstruction after mastectomy or in complex wound and soft tissue reconstruction. Instead of relying solely on a patient's own tissue flap or a standard implant, the surgeon uses an engineered tissue substitute, such as an advanced acellular matrix, to rebuild the physical structure and contour of the area. This approach can reduce the need for additional donor-site surgery and may support better integration with the patient's own tissue over time as the scaffold is gradually incorporated by the body. It is generally offered as an option within a broader reconstructive plan, discussed alongside the more traditional flap or implant choices, with the tradeoffs of material cost, healing pattern, and long-term durability weighed against those alternatives.
Anatomy & Axis Detail
Skin
When a code specifies skin generally rather than a named body region, it applies to procedures where the treated surface spans multiple areas or where the wound is not confined to a single trunk or extremity site captured by the more specific codes, such as extensive burns crossing several anatomic zones. Replacement of skin as a whole reflects the use of a bioengineered or acellular substitute across a wound too widespread or too irregular in distribution to attribute to one region, commonly seen in major burn resuscitation or generalized exfoliative skin loss. Because skin's structure and healing capacity vary considerably by location, documentation should specify the actual body areas covered whenever possible, reserving this general code for genuinely multi-regional or non-localized treatment so that the record reflects the true extent of skin involved rather than defaulting to it out of convenience.
Approach: External
External approach in New Technology applies to procedures performed directly on the skin, mucous membranes, or via direct visualization without penetrating a body cavity, such as applying or activating a device against the body surface. It contrasts with Percutaneous approaches, which require instrument entry through the skin rather than surface-level contact.
Device / Substance / Technology: Bioengineered Allogeneic Construct
This value denotes a bioengineered construct built from allogeneic, meaning donor-derived rather than the patient's own, cells and used as a tissue substitute in applications such as wound repair. It is distinguished from autologous cell therapies like gene-corrected keratinocyte products by its use of cells sourced from a donor rather than the patient. The allogeneic origin allows off-the-shelf availability without requiring patient-specific cell harvesting.
Qualifier: New Technology Group 7
As a qualifier value, Group 7 marks a code as belonging to the set of new technologies approved for use in the 2020-2021 fiscal year, a period that included a notable expansion of infectious-disease-related add-on codes. The label does not describe what the technology does; that detail sits in the table and other axis values. It is distinguished from adjoining groups solely by its approval-year cohort.
Coding & Documentation
Assignment depends on documentation identifying the specific new-technology material used and confirming that it physically replaced tissue rather than simply reinforcing what remained, since Replacement and Supplement are distinguished by whether structure was fully substituted versus augmented. The operative note should describe the extent of tissue removed and the material placed to take its structural role. A common error is coding a standard Replacement from the Medical and Surgical section instead of the New Technology equivalent because the specific product name was omitted from the note, or conflating this with a Supplement code when the material was actually layered onto existing tissue rather than replacing removed tissue.
Commonly Confused With
The key point of confusion is with Supplement procedures in the same body system, where material reinforces or augments tissue that is still present rather than replacing tissue that was removed; if any native structure remains and is simply being bolstered, Supplement applies instead. It is also distinguished from autologous flap reconstruction, which uses the patient's own tissue and is coded under different root operations entirely, and from standard implant-based breast reconstruction, which may not qualify for a New Technology code unless the specific advanced material used is documented.